niacinamide has been researched along with phosphotyrosine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, C; Buettner, R; Hedvat, M; Jensen, M; Jove, R; Schroeder, A; Scuto, A; Starr, R; Yang, F | 1 |
| Carr, BI; Wang, M; Wang, Z | 1 |
| Dent, P; Grant, S; Häussinger, D; Ogretmen, B; Park, MA; Reinehr, R; Voelkel-Johnson, C; Yacoub, A | 1 |
| Cho, E; Choi, KM; Chung, YH; Han, EH; Kang, M; Kim, B; Kim, E; Kim, JY; Shin, JH | 1 |
4 other study(ies) available for niacinamide and phosphotyrosine
| Article | Year |
|---|---|
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin E; DNA, Neoplasm; Glioblastoma; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Mutant Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Proteins; Phenylurea Compounds; Phosphorylation; Phosphotyrosine; Protein Binding; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Cells, Cultured; Vanadates | 2010 |
Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
Topics: Actins; Benzenesulfonates; Carcinoma, Hepatocellular; Cofilin 1; Cytoskeleton; Enzyme Activation; Humans; Liver Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Phosphorylation; Phosphotyrosine; Proto-Oncogene Proteins c-met; Pyridines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Signal Transduction; Sorafenib | 2010 |
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Topics: Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Fas Ligand Protein; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Phosphotyrosine; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sorafenib; src-Family Kinases; Vorinostat | 2010 |
Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Topics: Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Invasiveness; Niacinamide; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinolines; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2018 |